Abstracts and Awards – Vascular Discovery 2026

Abstracts Open:
Wednesday, October 22, 2025

Abstracts Close:
Tuesday, January 7, 2026 at 6:00 p.m. CST (UTC -6)

Abstract Withdrawl Deadline:
Monday, April 27, 2026 at 5:00 p.m. CST (UTC -6)

Rules and Guidelines for Abstract Submission

Submission deadline: January 7, 2026 at 6:00 p.m CST (UTC -6)

To ensure that your abstract receives proper scientific consideration, be sure to submit to the appropriate category.

Abstract Submission:

• Review Best Practice for Writing Abstracts
• Submit all abstracts in English.
• Authors should not "split" data to create several abstracts from one. If splitting is judged to have occurred, priority scores of related abstracts will be reduced.
• Abstracts containing identical or nearly identical data submitted from the same institution and/or individuals will be disqualified.
• Proofread abstracts carefully to avoid errors before submission. The abstract will be reviewed exactly as submitted.
• An abstract must have a short, specific title (containing no abbreviations) that indicates the nature of the investigation.
• Describe briefly the objectives of the study unless they are contained in the title. Include a brief statement of methods if pertinent. State findings in detail sufficient to support conclusions. Abstracts should not describe research in which the chemical identity or source of the reagent is proprietary or cannot be revealed.
• Use generic drug names.
• Do not begin sentences with numerals.
• Standard abbreviations may be used without definition. Nonstandard abbreviations (kept to a minimum) must be placed in parentheses after the first use of the word or phrase abbreviated.
• Do not include references, credits or grant support.
• Do not include the names or personal information of any patient participating in the study or trial.
• The character limit cannot exceed 2,500. Spaces and punctuation count as characters.

Author Name(s):

• The submitting author will be designated as the primary and presenting author unless otherwise specified. The presenting author must be listed on the abstract and can be listed anywhere in the author block.
• Acceptance notifications and correspondence are sent to the presenting author ONLY.
• All authors listed on the abstract must have actively participated in the research the abstract represents. The AHA reserves the right to remove an abstract from the program.
• Please review the author block carefully. Edits cannot be made after the deadline. Once submission is complete, the author block will be published as submitted. Additions or deletions of author names are not permitted after the submission deadline.

Acceptance:

• Submitters will be notified of acceptance/non-acceptance status via e-mail by early February 2026.
• Abstracts are reviewed in blinded fashion and selected on the basis of scientific merit. The conference Program Committees will determine whether the abstract is to be presented orally or by poster.
• Request oral or poster presentation on the properties tab of the submitter site (note that poster presentations may be selected for a moderated poster). Unless you select "poster only" the selection of one of these options will neither prejudice acceptance nor guarantee an oral presentation because abstracts will be arranged to fit into a thematic group for presentation. Although every effort will be made to accommodate your presentation request, there is no guarantee that you will present in the mode of your preference.
• Expenses associated with the submission and presentation of an abstract are the responsibility of the presenter.
• Presenting/submitting authors must register and pay associated fees for attendance at the conference. All abstract presentations (oral or poster) must be in-person.
• Abstracts selected will be published in an online version of the ATVB Journal.
• Accepted abstracts will not have been published (manuscript or abstract) prior to the date of this submission or presented at any national or international meeting prior to May 13, 2026. Abstracts are embargoed for release at date and time of presentation or time of AHA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation.
• Submission of an abstract constitutes a commitment by the authors to present if accepted. Failure to present, if not justified, will jeopardize future acceptance of abstracts.
• Recording Policy:
• Unauthorized recording of AHA Scientific Sessions, scientific conferences and the ASA International Stroke Conference is prohibited, whether by video, still or digital photography, audio or any other recording or reproduction mechanism. This includes recording of presentations and supporting audiovisual materials and of poster presentations and supporting poster materials.
• The American Heart Association and American Stroke Association reserve the rights to all recordings or reproductions of presentations at AHA/ASA scientific conferences and meetings.

Abstract Withdrawal:

• There is no guarantee that your abstract will not be published in the final program and the Journal unless request for withdrawal is received in writing by 5:00 PM CST April 27, 2026 (UTC -6). Please reference "VASCD26."

Abstract Revisions:

• After the submission deadline, your abstract submission is consdered final and cannot be edited. No proof pages will be sent to authors.
  • Abstracts ma not be revised or in any way resubmitted
  • Additions or deletions of author names will not be permitted.
• Proofread abstracts carefully to avoid errors before submission.

Use of Automated Assistive Writing Technologies and Tools:

• The use of automated assistive writing technologies and tools (commonly referred to as artificial intelligence or machine learning tools) is permitted provided that their use is documented, and authors assume responsibility for the content. As with human generated content, authors are responsible for the accuracy, validity and originality of computer-generated content. Automated assistive writing technologies do not qualify for authorship as they are unable to provide approval or consent for submission.
• If the use of these technologies has involved the research design, the tools should be documented in the Methods section of the abstract. For additional information, see the World Association of Medical Editor recommendations.
• For your abstract submission, you will need to indicate the use of these tools.

Presentation:

• All presentations and question-and-answer sessions will be conducted in English. Presenters may request assistance from the moderator who will repeat or rephrase questions from the audience or may ask a colleague in the audience to assist with translation.
• References to work previously published by other authors must include citations at the bottom of the appropriate slides.
• Unauthorized recording of the conference is prohibited, whether by video, still or digital photography, audio or any other recording or reproduction mechanism. This includes recording of presentations and supporting AV materials and of poster presentations and supporting poster materials.
• All oral presentations must be in electronic format. Electronic presentations must be submitted 12 business hours in advance of the session start time. Instructions will be provided upon acceptance.

Looking for recommendations on how to improve your abstract? We highly recommend you view these recommendations from AHA Journals.

The suggestions below are intended to provide guidance on abstract writing.

Title
To the extent the data permits, make the title dynamic and conclusive, rather than descriptive. For example, "Hypoxia Inhibits Kv1.5 Channels in Rat Pulmonary Artery Smooth Muscle Cells" is preferable to "Effects of Hypoxia on Kv1.5 Channels." Explicit titles denoting the findings should be used (not "Investigations of…," "Studies of…," etc.)

Structure
Abstracts should have the following identifiable sections: Introduction, Hypothesis, Methods, Results and Conclusions.

Abbreviations
Abbreviations may be used after they are spelled out or defined. Use generic, not commercial, names for all therapeutic agents.

Category
Be sure to select the correct abstract category. Category selection determines which team grades the abstract. If you select the appropriate category, your abstract will be blindly graded by experts familiar with the science of the category.

Common mistakes

1. Failure to state the hypothesis. We advise a formal statement such as, "We assessed the hypothesis that…"
2. Failure to state a conclusion. We encourage a final sentence that says: "In conclusion…"
3. Failure to state sample size. The reviewers want to assess the quality of the data – they need a mean SEM and a sample size.
4. Excessive use of abbreviations. All but the most standard abbreviations should be defined, and most abstracts should have less than 3 abbreviations.

Traps to avoid

1. Typographical errors
2. References cited in the abstract
3. Not providing context or a statement of relevance that provides the rationale for your study.
4. Complex graphics. Simple line or bar graphs are most appropriate. Ensure the font size is adequately large on each axis to be visible. Check a printed version of the abstract before submitting.
5. Duplicative work

Remember: Make sure your abstract is clear, concise, and follows all rules. Show your abstract to a colleague prior to submission and modify accordingly. A fresh pair of eyes will help spot any errors and will ensure the final package is ready for submission.